Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.850
-0.150 (-5.00%)
At close: Mar 19, 2026, 4:00 PM EDT
2.940
+0.090 (3.16%)
After-hours: Mar 19, 2026, 7:55 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
-$2,666,742
Market Cap
216.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | 10 | 2 | 25.00% | 10 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Alector | 103 |
| Tonix Pharmaceuticals Holding | 81 |
| Keros Therapeutics | 78 |
| Surrozen | 41 |
| Sol-Gel Technologies | 34 |
| Fennec Pharmaceuticals | 32 |
ELDN News
- 8 hours ago - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - GlobeNewsWire
- 3 days ago - Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
- 9 days ago - Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - GlobeNewsWire
- 10 days ago - NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PRNewsWire
- 15 days ago - Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 7 weeks ago - Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - GlobeNewsWire